Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries

Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries

Abstract Background Respiratory syncytial virus (RSV) frequently causes acute lower respiratory infection in children under 5, representing a high burden in Gavi-eligible countries (mostly low-income and lower-middle-income). Since multiple RSV interventions, including vaccines and monoclonal antibo...

Full description

Bibliographic Details
Main Authors: Xiao Li, Lander Willem, Marina Antillon, Joke Bilcke, Mark Jit, Philippe Beutels
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Medicine
Subjects:
Respiratory syncytial virus
Cost-effectiveness analysis
Maternal vaccination
Monoclonal antibody
Disease burden
Expected Value of Partially Perfect Information
Online Access:http://link.springer.com/article/10.1186/s12916-020-01537-6

Internet

http://link.springer.com/article/10.1186/s12916-020-01537-6

Similar Items